Biologics are one of the fastest growing category of drugs—and one of the most expensive—making it challenging to balance cost with safety and efficacy. And it's even more challenging to incorporate unbranded biologics and biosimilars into benefits plans. Gus Georgiadis, Area President, Gallagher Benefit Services, cuts through the confusion on how these therapies work and outlines what benefits managers need to know.
Listen to this podcast to get answers to the following questions:
- What's the difference between biologics, unbranded biologics, and biosimilars?
- How do employers address changes to biologic therapies?
- What's the impact of unbranded biologic and biosimilars on the overall healthcare landscape?
- How do I determine the net cost to my benefits plans?
Listen to learn what you should consider when evaluating benefits plans with multiple biologic alternatives.